Adial Pharmaceuticals, Inc. (AZR) stock
AZRNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ADIL
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Oct 21, 2026Score 5/30
Share price
Not available yet
Price, market cap and P/E appear here once daily prices are connected.
Adial Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Adial Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$57.68M. For fiscal 2025 it was -$7.80M. The highest annual figure on record is -$995.29K in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.80M | – |
| FY2024 | Dec 31, 2024 | -$8.28M | – |
| FY2023 | Dec 31, 2023 | -$6.89M | – |
| FY2022 | Dec 31, 2022 | -$10.86M | – |
| FY2021 | Dec 31, 2021 | -$19.29M | – |
| FY2020 | Dec 31, 2020 | -$10.93M | – |
| FY2019 | Dec 31, 2019 | -$8.24M | – |
| FY2018 | Dec 31, 2018 | -$6.99M | – |
| FY2017 | Dec 31, 2017 | -$995.29K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$52.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.89M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.88M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.21M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.29M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.78M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.60M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.98M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.40M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.84M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.47M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.82M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.09M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.75M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.16M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.25M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.09M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.82M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.74M | – |
| Q1 FY2018 | Mar 31, 2018 | -$339.51K | – |
| Q4 FY2017 | Dec 31, 2017 | -$321.79K | – |
| Q3 FY2017 | Sep 30, 2017 | -$262.42K | – |
| Q2 FY2017 | Jun 30, 2017 | -$241.49K | – |